Latest Headlines

Latest Headlines

Bayer wins new use for fast-moving cancer drug Stivarga

Bayer's new cancer drug Stivarga has already added a notch to its belt. Cleared by the FDA last year to treat colorectal cancer, the drug is now approved as a treatment for a rare form of gastric cancer, gastrointestinal stromal tumors.

Bayer cancer drug races through FDA approval

Fast track indeed. Only three months after granting accelerated-approval status to Bayer's blockbuster hopeful regorafenib, a treatment for colorectal cancer, FDA gave the drug its final blessing.

Timeline on regorafenib (Stivarga) development

Three months after landing FDA fast-track review status for regorafenib, Bayer 's top cancer prospect, today the agency delivered an approval as a treatment for colorectal cancer. The approval comes after a tumultuous lawsuit filed in 2009 by Onyx Pharmaceuticals ($ONXX), claiming the compound can be distinguished from Nexavar by only a single atom. Here's a look back at regorafenib's history.

UPDATED: Bayer, Onyx nab speedy FDA OK for regorafenib, prices at $9,350

Only three months after nabbing FDA fast-track review status for regorafenib, Bayer's top cancer prospect, the agency handed out a speedy approval this afternoon as a new treatment for metastatic colorectal cancer. The double-quick regulatory OK completes Bayer's quick sprint through the late-stage development process, paving the way to commercialization work expected to generate peak sales of $1.25 billion a year or more.

UPDATED: Onyx wins accelerated approval for myeloma drug Kyprolis

Onyx nailed an FDA approval today for the multiple myeloma drug Kyprolis (carfilzomib), overcoming the naysayers who were skeptical that the agency would hand out an accelerated OK for a new drug on just mid-stage data drawn from a single-arm study.

FDA offers Bayer, Onyx fast review for regorafenib

Bayer HealthCare and Onyx Pharmaceuticals won an inside track at the FDA today for their closely-watched cancer drug regorafenib.

ASCO Highlights: Top stories from this year's meeting

Bristol-Myers presents promising PD-1 data; Genentech boasts solid T-DM1 results; GSK aces pivotal studies; Ariad's ponatinib shines; Bayer's regorafenib delays stomach cancer; Zytiga impresses in prostate cancer; Aveo makes a PhIII case for tivozanib; Seattle Genetics expands its CD-30 horizons; ADCs arrive.

Buzz: Is Bayer looking to buy Onyx Pharma?

Reuters reported today that Bayer is looking to close a multibillion-euro acquisition deal, quoting sources who say that an announcement could be "imminent."

Bayer bolsters blockbuster case for regorafenib with new PhIII data

Bayer has racked up a fresh set of preliminary late-stage data that will bolster its plans to market regorafenib for a range of cancers.

Bayer details positive PhIII data on cancer blockbuster hopeful regorafenib

Bayer HealthCare took another step toward a planned marketing application for the cancer drug regorafenib today as it unveiled the late-stage colorectal cancer data that it plans to take to